Jun 13, 2023 · Anti-obesity drug sales could increase 18x from 2022-30 to $44 billion, our in-depth analysis shows, with Novo Nordisk and Eli Lilly leading the pack. Here, Bloomberg Intelligence Senior...

Feb 23, 2022 · Michael Shah graduated from the London School of Economics with a BSc in Accounting and Finance. He has been focused on the healthcare sector for the past ten years, initially...

Jun 1, 2023 · Michael Shah, Senior Industry Analyst at Bloomberg Intelligence, commented: “We expect Novo Nordisk’s franchise (Wegovy, Saxenda, oral semaglutide, CagriSema) and Eli Lilly’s tirzepatide to dominate with shares of 54% and 46% respectively, while contributions from less-effective AOBs are negligible.

May 31, 2023 · “We expect Novo Nordisk's franchise (Wegovy, Saxenda, oral semaglutide, CagriSema) and Eli Lilly's tirzepatide to dominate with shares of 54% and 46% respectively, while contributions from less-effective AOBs are negligible,” said Michael Shah, senior industry analyst at Bloomberg Intelligence.

Obesity Doctors Envisage More Access; Hurdles Persist -- Michael Shah talks about the findings from his survey of 100 doctors about the biggest weight-loss drugs. Canada Banks Might Need Charges to Boost Leverage -- Paul Gulberg explains why the banks may build additional loan provisions and face o…

Analyst-Equity at Bloomberg LP (UK), Discover Michael Shah's known position history, network and 5 relationships. Find out about his known public assets.

Bloomberg Live brings together the expertise of the largest newsroom in the world with the immense data and analytical power of Bloomberg Intelligence and Bloomberg Global Data to enable our celebrated moderators and speakers to …

Aug 21, 2023 · Michael R. Bloomberg, the founder of the financial data colossus Bloomberg L.P., announced a new chief executive and president on Monday, a possible indication of who will take over for him...

Jan 6, 2022 · Seema Shah, chief global market strategist at Principal Global Advisors, discusses anticipating market volatility in 2022, inflation expectations settling above the 2% target, and why an ...